CN101785813B - Chinese herba preparation for regulating lipid and reducing weight - Google Patents
Chinese herba preparation for regulating lipid and reducing weight Download PDFInfo
- Publication number
- CN101785813B CN101785813B CN2010101104160A CN201010110416A CN101785813B CN 101785813 B CN101785813 B CN 101785813B CN 2010101104160 A CN2010101104160 A CN 2010101104160A CN 201010110416 A CN201010110416 A CN 201010110416A CN 101785813 B CN101785813 B CN 101785813B
- Authority
- CN
- China
- Prior art keywords
- blood
- lipid
- reducing weight
- fat
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese herba preparation for regulating lipid and reducing weight, made by sticktight, hawthorn, roxburghrose, medlar and salvia miltiorrhiza. The medicines are combined to achieve synergistic effect of efficacies of all medicines, thus effectively removing stasis and activating blood, helping digestion, nourishing liver and kidney and replenishing qi to invigorate the spleen. Most medicines in the invention are food and have definite curative effect, thus being applicable to application for a long time, and price is low, thus being easy to develop and apply.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine preparation of regulating lipid and reducing weight.
Background technology
Cause that fat reason motherland medical science also early has argumentation, conclude and get up to have following four aspects that 1. natural endowment is relevant, i.e. inherited genetic factors; 2. have a liking for food highgrain savoury, the diet excess, drug on the market for nutritional labeling, make in the lipopexia body due to; 3. drowsiness sitting, physical exertion is very few, and body obviously reduces the consumption of energy, causes overnutrition, fat is filled in skin and obesity; 4. body visceral dysfunction, stagnation of QI due to depression of the liver, insufficiency of the spleen mistake fortune, suffering from a deficiency of the kidney gasification dereliction of duty, internal injury prolonged illness is given birth in expectorant is turbid, or affection of exogenous damp again, and the heresy that causes phlegm-damp is accumulated in the body and is caused fat fat.Total face is sayed it, and this disease belongs to the disease of deficiency in origin and excess in superficiality, the deficiency in origin person is insufficiency of the spleen, suffer from a deficiency of the kidney, the deficiency of vital energy also; Mark real person, phlegm resistance and stagnation of QI due to depression of the liver blood stasis also, related internal organs are with spleen, liver. kidney is main, causes frequent constipation certain relation is also arranged with the dereliction of duty of preaching of impairment of dispersing and descending function of the lung, large intestine in addition.By cause of disease classification, substantially obesity is reduced 8 kinds according to modern medicine study: 1. heritability is fat; 2. endogenous obesity; 3. hyperphagia property is fat; 4. moving less property is fat; 5. hypothalamic obesity; 6. medicine source domestic animal is fat; 7. psychological obesity; 8. nerve or physiological are fat.Wherein with 3,4 two kind of reason more sees, also can three kinds of reasons have concurrently.Hyperlipemia is a commonly encountered diseases, causes arteriosclerosis easily, and then causes the generation of cardiovascular and cerebrovascular disease, threatens people's quality of life and life security; Obesity is meant the fatty tissue of overheap in the body, not only influences the normal physiological function of whole machine body, can increase the sickness rate of diseases such as cardiovascular and cerebrovascular disease, diabetes, fatty liver, tumor, endocrine disturbance simultaneously.The lipids contents of obese people is apparently higher than normal population; Increase along with obese degree; Lipids contents is in rising trend, lipid lowerers of using clinically at present and appetrol untoward reaction serious (like the rhabdomyolysis of Statins), and the treatment cost is high; Very big with this disease contradiction of need taking medicine for a long time, and effect is not satisfactory.
Summary of the invention
Therefore still there is demand in human Chinese medicine preparation to the better regulating lipid and reducing weight of curative effect; Up to now, also do not find the report of any relevant pharmaceutical composition of the present invention, for solving the problem that present regulating lipid and reducing weight exists; Therefore the inventor according to hyperlipemia with fat the two have dependency; Start with from blood fat reducing, can promote lipid mobilization to a certain extent, help fat-reducing simultaneously; Through for a long time, research repeatedly, constantly research improves, and has found the regulating lipid and reducing weight Chinese medicine preparation of better efficacy finally, has accomplished the present invention.
The consumption of drug group composition of the present invention is that inventor's process gropes to sum up to get for a long time in a large number, and the each component consumption all has curative effect preferably in following weight parts:
Herba Bidentis Bipinnatae 15-25 part, Fructus Crataegi 10-20 part, Fructus Rosae Normalis 10-20 part, Fructus Lycii 5-15 part, Radix Salviae Miltiorrhizae 10-20 part.
Medicament selection Herba Bidentis Bipinnatae of the present invention, Fructus Crataegi, Fructus Rosae Normalis, Fructus Lycii, Radix Salviae Miltiorrhizae make up, and make each efficacy of drugs produce synergism these drug regimens, thus effectively removing blood stasis and activating blood flow, help digestion and remove long-pending, nourishing the liver and kidney, replenishing QI to invigorate the spleen.Herba Bidentis Bipinnatae has another name called terrible Ge pin, Herba bidentis parviflorae, Herba Bidentis Bipinnatae, Rhizoma Homalomenae among the present invention.For Compositae annual herb plant, be grown in limit, field, roadside, wilderness, hillside, limes marginis, national most of areas all has distribution.This property of medicine temperature, bitter in the mouth are nontoxic.China's traditional medicine is thought: it has effects such as heat-clearing and toxic substances removing, removing blood stasis and activating blood flow, hemostasis antidiarrheal.Experimentation proves: this medicine can make β one lipoprotein and cholesterol level reduce. and tangible anti-artery thrombosis effect is arranged.Clinical practice proves: Herba Bidentis Bipinnatae can prevent effects such as cerebral thrombosis, prevention of arterial sclerosis effectively.Herba Bidentis Bipinnatae contains compositions such as alkaloid, Saponin, flavonoid glycoside, amaroid, aminoacid, vitamin and tannin, and wherein content of amino acids is particularly abundant, up to 17.5%, very high edibility is arranged simultaneously.This medicine medicine source is wide, inexpensive, and curative effect is high, has no side effect.Fructus Crataegi, the sweet tepor of nature and flavor acid is nontoxic, goes into spleen, stomach, Liver Channel, and the effect of digestion-promoting spleen-invigorating, circulation of qi promoting dissipating blood stasis is arranged.Cure mainly meat stagnation, gastral cavilty distension, dysentery stomachache, blood stasis amenorrhea, postpartum stagnation, trusted subordinate's twinge, hyperlipemia etc.Modern pharmacological research finds to have persistent blood fat reducing, expansion coronary vasodilator, antiarrhythmic effect.Fructus Crataegi contains multiple organic acid, and it is greasy to dispel fat, eats Fructus Crataegi for a long time and can degrease protects the liver, and its enlargement disappears.Fructus Crataegi contains multiple flavonoid glycoside and complicated poly flavane and dimerization flavanoid again, significant blood vessel dilating is arranged, brings high blood pressure down, cholesterol reducing and cardiotonic, so the normal food of hypertension, hyperlipidemia, obese patient.Fructus Rosae Normalis has another name called Wen Xianguo, send the spring to return, and is Rosaceae Rosa machaka.Containing abundant vitamin C, superoxide dismutase, Fructus Rosae Normalis flavone, Fructus Rosae Normalis polysaccharide and multiple human body must aminoacid.Nutritious, edible safety.Traditional medicine mainly is used as medicine its fruit, root, is used to help digestion, treatment of diseases such as antidiarrheal, expelling summer-heat and food stagnation abdominal distention, dysentery, enteritis, hypertension, angiorrhexis are hemorrhage, vitamin C deficiency.In recent years research is reported: Fructus Rosae Normalis also has functions such as the body's immunity of adjusting, detoxifcation, calmness, slow down aging, atherosclerosis, antitumor.Through acute toxicity, long term toxicity and mutagenesis, teratology testing, do not see toxic action, mutagenic action and embryo's teratogenesis prove thorn pear innocuous substance.Experimentation confirms: Fructus Rosae Normalis has protective effect to the mouse aging kidney injury; Fructus Rosae Normalis extract can be adjusted the hyperlipemia lipid metabolism, reduces blood viscosity, alleviate lipid peroxidation injury, thereby has the effect that the atherosclerosis speckle forms.Fructus Lycii also is FRUCTUS LYCII, is tonic Chinese medicine simply, and its property is put down sweet in the mouth, can nourishing the liver and kidney, replenishing YIN and blood, replenishing vital essence to improve eyesight; Be used for soreness of the waist and knees, have a dizzy spell, disease such as blood deficiency and yellow complexion, visual deterioration, deficiency of the kidney seminal emission.Modern medicine study shows Fructus Lycii except that containing higher protein, saccharide, dietary fiber, mineral, carotene, multivitamin, also contains betanin, linoleic acid, globulariacitrin, inosine, several amino acids etc.The ability vision protection improves liver, renal function; Improve myocardial ischemia and arteriosclerosis; Blood pressure lowering, flat blood glucose; Mediator's body immunity function; Fructus Lycii has certain accent fat effect to human body, and is especially obvious to the triglyceride reducing effect.Zoopery shows that Fructus Lycii can reduce the peroxidating of blood fat, blood glucose and the low-density ester gp of animal pattern, improves oxidation resistance, DNA damage and the insulin resistant of diabetic mice.Radix Salviae Miltiorrhizae, the little hardship of property is slightly cold, the GUIXIN Liver Channel.Its main component has liposoluble constituent TANSHINONES, TANSHINONES A, TANSHINONES B, cryptotanshinone, dihydrotanshinone etc., water soluble ingredient danshensu etc.Have functions such as blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind, stasis-dispelling and pain-killing.In recent years research confirms: its pharmacological action has (1) to activate fibrinolytic system, reduces blood viscosity, and acceleration is flowed slowly or the flow velocity of the hemocyte that the stasis of blood stagnates; (2) promote that capillary network is open, little vasodilation, reverse the anomalous structure of blood vessel wall; (3) reduce the gathering of calcium ion in histiocyte that hypoxic-ischemic causes, antagonism calcium ion; (4) remove oxygen-derived free radicals, safeguard the normal function of cell, improve the activity of ATP enzyme; (5) strengthen the erythrocyte immune absorbability, prevent that immune complex strengthens the immunologic function of cell body fluid in tissue deposition in the circulation; (6) the protection Liver and kidney promotes liver cell regeneration etc.This medicine clinical practice very extensively.Especially with treatment coronary heart disease, cerebrovascular disease, all kinds heart failure, infantile pneumonia, chronic renal failure with to improve the liver function effect obvious, but adjuvant therapy rheumatoid arthritis and aspect curative effect such as dizzy be certainly simultaneously.Traditional medicine is thought: Herba Bidentis Bipinnatae has effects such as heat-clearing and toxic substances removing, removing blood stasis and activating blood flow, hemostasis antidiarrheal; Fructus Crataegi has the effect of digestion-promoting spleen-invigorating, circulation of qi promoting dissipating blood stasis; Fructus Lycii nourishing the liver and kidney, replenishing YIN and blood, replenishing vital essence to improve eyesight; Fructus Rosae Normalis helps digestion, antidiarrheal, expelling summer-heat and food stagnation abdominal distention; Radix Salviae Miltiorrhizae has functions such as blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind, stasis-dispelling and pain-killing.The main Therapeutic Principle of regulating lipid and reducing weight of the present invention is: removing blood stasis and activating blood flow, help digestion and remove long-pending, nourishing the liver and kidney, replenishing QI to invigorate the spleen.Carrying out prescription screening according to this principle, is main with blood lipid regulation, reaches the double purpose of lowering blood-fat and reducing weight simultaneously.Herba Bidentis Bipinnatae, Fructus Crataegi, Radix Salviae Miltiorrhizae, Fructus Lycii all have effect for reducing fat among the present invention: modern study is thought: Fructus Lycii fatty main component be linoleic acid, prevent and treat effects such as hypertension, arteriosclerosis, lowering blood-fat and reducing weight.Radix Salviae Miltiorrhizae contains TANSHINONES, iso tanshinone, VE etc., and blood circulation promoting and blood stasis dispelling, lowering blood-fat and reducing weight, calming heart and tranquilizing mind effect are arranged.The kind inner product that disappears of Fructus Crataegi, the oiling that can disappear are bored with, and be long-pending through helping digestion, and reaches the effect of lowering blood-fat and reducing weight, and the concurrent hypertension of obesity patient, coronary heart disease, hyperlipemia etc. are more had benifit.Herba Bidentis Bipinnatae can make beta lipoprotein and cholesterol level reduce. and tangible anti-artery thrombosis effect is arranged.In recent years; Application along with cytobiology, Protocols in Molecular Biology; The blood fat reducing approach of part Chinese traditional medicines depressing lipid, effect link and drug effect target spot are illustrated gradually, for the exploitation of Chinese traditional medicines depressing lipid provides theoretical support, can further be familiar with Chinese medicine lowering blood-fat and reducing weight approach and mechanism thereof.Confirm: Fructus Crataegi ketone can reduce Serum TC, the content of TG, and the expression of raising rat liver LDLR-mRNA strengthens Antioxidation Ability of Rats; TANSHINONES can make low density lipoprotein, LDL, and cholesterol levels descends; The Fructus Lycii total polysaccharides is utilized and cholate combines to form complex, and absorption of bile acid promotes its drainage; Cause lipid emulsifying obstacle; Or, constitute physical barriers at intestinal formation gel, influence cholesterol reduces exogenous lipid with digestive enzyme, bile acid micelle and contacting of intestinal mucosa absorption.Fructus Crataegi has remarkable reduction hyperlipidemia rabbit anteserum TC; The effect of TG and rising HDL; The Fructus Crataegi water decoction can increase cholesterol biosynthesis rate-limiting enzyme vigor in hepatocyte microsome and the mucous membrane of small intestine homogenate, improves HDL and concentration of component thereof in the serum, suppresses the synthetic of endogenous lipid then.2. protect Liver and kidney, enhancing human body immunity power, the traditional Chinese medical science belongs to caused by liver and kidney deficiency, insufficiency of the spleen phlegm-damp, qi depression to blood stasis etc. with hyperlipemia clinically, so treat appropriate to the occasion many with liver and kidney tonifying, invigorating the spleen for eliminating dampness, drug for invigorating blood circulation and eliminating stasis.Fructus Rosae Normalis has functions such as the body's immunity of adjusting, detoxifcation, calmness, slow down aging, atherosclerosis, antitumor among the present invention.Experimentation also confirms: Fructus Rosae Normalis has protective effect to the mouse aging kidney injury; Fructus Lycii nourishing the liver and kidney, raising liver, renal function, replenishing YIN and blood, replenishing vital essence to improve eyesight can not only suppress fat at intrahepatic deposition, and can promote liver cell regeneration.Radix Salviae Miltiorrhizae strengthens the immunologic function of cell body fluid, and the protection Liver and kidney promotes liver cell regeneration, clinically is used to treat coronary heart disease, treatment cranium disease of brain, treatment renal failure.Hawthorn digesting spleen invigorating, circulation of qi promoting dissipating blood stasis, food can protect the liver by degrease for a long time.The present invention has the regulating lipid and reducing weight effect, protects Liver and kidney, enhancing human body immunity power simultaneously.3. toxic and side effects is minimum, has bright prospects: in the prescription Fructus Crataegi, Fructus Lycii, Fructus Rosae Normalis, Herba Bidentis Bipinnatae be medicine be again food.Fructus Rosae Normalis proves that through acute toxicity, long term toxicity and mutagenesis, teratology testing the Fructus Rosae Normalis goods belong to innocuous substance; Fructus Lycii is the food and the medicine of strengthening by means of tonics since ancient times; The hawthorn digesting spleen invigorating can eat for a long time; Herba Bidentis Bipinnatae is usually cooked edible in the locality.Therefore have bright prospects aspect food, health product and the drug development.
According to motherland's medical analysis, the regulating lipid and reducing weight method should be with invigorating the spleen and benefiting QI, the eliminating phlegm dampness removing; Soothing the liver circulation of qi promoting, activating blood circulation to dissipate blood stasis; Invigorating kidney qi, loosening bowel to relieve constipation are main, are aided with promote qi circulation digestion promoting, blood fat reducing, eliminating pathogens by phlegm elimination and purgation respectively again, methods such as relieving exterior-interior syndrome; Make lung qi dispersing gas, middle accent taste, following reason Liver and kidney; Thereby regulate the whole machine body function, superabundant fats decomposes in the acceleration bodies, to reach the purpose of regulating lipid and reducing weight.Its mechanism has: reduce the absorption of exogenous lipid; Reduce the synthetic of endogenous lipid; Promote the transhipment and the drainage of lipid; Four types of adjusting lipid metabolism etc.Contain the active action component of similar inhibition pancreatic lipase like Fructus Crataegi, reduce the synthetic of endogenous lipid; The Fructus Lycii total polysaccharides is utilized and cholate combines to form complex, reduces the absorption of exogenous lipid; Danshensu can activate the LDLR expression of gene and induce LDLR transcriptional level inhibition endogenous cholesterol to synthesize and the performance effect for reducing fat.Fructus Rosae Normalis can reduce cholesterol, triacylglycerol (TG) and the LPO level in the blood, and SOD activity improving is adjusted the hyperlipemia lipid metabolism, reduces the blood viscosity, alleviated lipid peroxidation injury, alleviates the arterial disease degree, prevents hypertension and arteriosclerosis.Herba Bidentis Bipinnatae can better reduce the caused body weight gain of high fat diet, reduces body fat content, liver index; Reduce TC, TG, LDL-C, rising HDL-C improves high fat rat blood serum SOD vigor, reduces MDA, and good lipoid peroxidization resistant is arranged; Significantly reduce high fat rat blood serum AST, ALT.
The specific embodiment
The present invention is processed by the former medicine of following weight portion: Herba Bidentis Bipinnatae 15-25 part, Fructus Crataegi 10-20 part, Fructus Rosae Normalis 10-20 part, Fructus Lycii 5-15 part, Radix Salviae Miltiorrhizae 10-20 part.
The present invention takes by weighing according to the said medicine weight proportion, mixes, pulverizes, sieves, sterilizing, processes graininess; The present invention can also take by weighing according to the said medicine weight proportion, mixes, pulverizes, sieves, sterilizing, processes decoction or capsule.
Embodiment 1: the present invention is processed by the former medicine of following weight portion: 15 parts of Herba Bidentis Bipinnatae, 10 parts of Fructus Crataegis, 10 parts of Fructus Rosae Normalis, 5 parts of Fructus Lyciis, 10 parts of Radix Salviae Miltiorrhizaes.
Embodiment 2: the present invention is processed by the former medicine of following weight portion: 20 parts of Herba Bidentis Bipinnatae, 15 parts of Fructus Crataegis, 15 parts of Fructus Rosae Normalis, 10 parts of Fructus Lyciis, 15 parts of Radix Salviae Miltiorrhizaes.
Embodiment 3: the present invention is processed by the former medicine of following weight portion: 25 parts of Herba Bidentis Bipinnatae, 20 parts of Fructus Crataegis, 20 parts of Fructus Rosae Normalis, 15 parts of Fructus Lyciis, 20 parts of Radix Salviae Miltiorrhizaes.
Effect of drugs
(1) zoopery:
1. material
1.1 animal and feeding environment are purchased male Sprague-Dawley (SD) rat from the laboratory animal department of the Chinese Academy of Sciences of Wuhan Tongji Medical Univ., the SPF level, and body weight 170 ± 30g divides cage to feed, and 5 in every cage keeps cleaning in the cage.The Animal House temperature is 19～25 ℃, and relative humidity is 40%～60%, and light is the circulation of 12h light and shade.
1.2 instrument and equipment Hitachi 7179 automatic clinical chemistry analyzers, TU1901 ultraviolet spectrophotometer (Beijing is general analyses), electronic balance (the two outstanding Group Co.,Ltd of the U.S.).BM-VIII biological tissue embedding machine, freezing stage (Xiaogan City great achievement medical apparatus company limited), DMR+Q550 type pathological image analyser (German Leica company), Japanese Olympus all purpose microscope.
1.3 medicine
1.3.1 the regulating lipid and reducing weight medicine is prepared into granule by haw thorn Chinese wolfberry fruit Herba Bidentis Bipinnatae Fructus Rosae Normalis Radix Salviae Miltiorrhizae prescription.Herba Bidentis Bipinnatae is picked up from the field, identifies through my professor Yang Zhuanyun of school department of pharmacy, is bidens pilosa (Bidnsbipinnata L.), all herbal medicine.All the other purchase the medical market in the Nanyang, all are accredited as genuine piece through pharmacognosy professor.
1.3.2 other drug control drug: lovastatin capsule; Material is used in modeling: propylthiouracil Adeps Sus domestica, sodium cholate cholesterol.
1.4 reagent
The reagent name lot number place of production/company
ALT test kit 200801 Zhongsheng Beikong Biological Science & Technology Co., Ltd.
AST test kit 200801 Zhongsheng Beikong Biological Science & Technology Co., Ltd.
TG test kit L71115AK01 Beijing Leadman Biochemistry Technology Co., Ltd.
TC test kit L71030AJ01 Beijing Leadman Biochemistry Technology Co., Ltd.
GLU test kit L71225AL01 Beijing Leadman Biochemistry Technology Co., Ltd.
Bio-engineering research institute is built up in SOD test kit 20070806 Nanjing
Bio-engineering research institute is built up in MDA test kit 20070806 Nanjing
2. method
2.1 experiment is divided into groups and administration
Healthy male SD rat is divided into 4 groups at random, 10 every group.1. normal control group (abbreviation normal group); 2. model control group (abbreviation model group); 3. lovastatin matched group (be called for short lovastatin group); 4. regulating lipid and reducing weight medicine group; Begin experiment after in constant temperature (19～25 ℃), relative humidity 40%～60% environment, adapt to raising for 1 week with normal diet.Except that normal group feed normal diet, all the other respectively organize equal feed high lipid food, and (the high lipid food prescription is: cholesterol 1%, Adeps Sus domestica 10%, sodium cholate 0.3%, 0.2% propylthiouracil, normal feedstuff 88.5%.Simultaneously, normal group and model group give with volume normal saline (5ml/kg) every day.Each administration group gives lovastatin suspension (2mg/kg), regulating lipid and reducing weight medicine (5ml/kg) respectively every day, and each is organized medication and is the filling stomach.Weigh the adjustment dosage weekly 1 time.
2.2 collection of specimens
In 10 weeks of continuous irrigation stomach, after water 12h is can't help in last administration fasting, weigh; With 10% chloral hydrate 3ml/kg intraperitoneal injection of anesthesia, lie on the back and be fixed on the Mus plate heart extracting blood 2～5ml; And cut off breast fast, and begin from aortic arch, separate and clip thoracic aorta and heart; Cut off the abdominal cavity and get liver, take by weighing the liver quality; Get kidney, separate kidney fatty tissue on every side, take by weighing fat mass.With neutral buffered formalin solution fixedly aorta, heart and liver.
2.3 observation index and assay method
2.3.1 general index is weighed weekly 1 time; Observe rat behavior, diet, feces, hair and animal dead situation;
2.3.2 calculate body weight gain rate body weight gain rate=(execution precursor quality-body constitution amount when experiment begins)/body constitution amount * 100% when experiment begins
2.3.3 calculate perirenal fat proportion perirenal fat proportion=perirenal fat quality/body constitution amount * 100%
2.3.4 calculate liver index liver index=liver weight in wet base/body constitution amount * 100%
Press the WHO recommended formula, AI=(TC-HDL-C)/HDL-C 2.3.5 calculate AI (AI).
2.3.6 blood parameters detects 4 ℃ of centrifugal 10min of low temperature 3000rpm of blood sample, separation of serum, sealing ,-20 ℃ cold deposit to be checked.Respectively organize rat blood serum HDL-C, TC, TG, LDL-C, GLU, AST, ALT content with automatic clinical chemistry analyzer mensuration, determination step and computing formula are all operated in strict accordance with the test kit description; Serum MDA is measured and is adopted thiobarbituricacid (TBA) colorimetric analysis, and the SOD vitality test adopts xanthine oxidase, and determination step and computing formula are all operated in strict accordance with the test kit description.
2.3.7 morphological observation is selected two aortas, cardiac muscle, liver specimens for every group, transparent, the waxdip embedding of dewatering, section and paster, dewaxing HE dyeing, transparent, the sealing of dehydration, and optical microscope is observed morphological change down.
2.4 the statistical method initial data adopts SPSS10.0 statistical software analyzing and processing; The result representes with
; Measurement data utilization one factor analysis of variance carries out comparing between each group, and significance level is a standard with 0.05 and 0.01.Relatively adopt F check and q check between group.
3. result
3.1. body weight gain rate, perirenal fat proportion, liver index, AI are visible by table 1: 1. with normal group relatively, model group body weight gain rate, perirenal fat proportion, liver index, AI (AI) all significantly increase (P＜0.01 or P＜0.05); 2. compare with model group, each medication group all can effectively reduce body weight gain rate, perirenal fat proportion, liver index (P＜0.01), and the reduction of AI treats that the effect of reagent group is remarkable.
Table 1 body weight gain rate, perirenal fat proportion, liver index, AI
Group number of animals body weight gain rate (%) perirenal fat proportion (%) liver index (%) AI (AI)
Normal group 10 16.47 ± 5.00 0.19 ± 0.06 2.51 ± 0.18 0.45 ± 0.14
Model group 10 31.17 ± 6.63
Dd0.76 ± 0.06
Dd3.19 ± 0.23
Dd2.89 ± 0.90
d
Lovastatin group 10 19.67 ± 4.95
Ee0.44 ± 0.07
Ee2.67 ± 0.23
Ee1.93 ± 0.87
Regulating lipid and reducing weight medicine 10 18.67 ± 8.61
Ee0.28 ± 0.11
Ee2.68 ± 0.26
Ee0.75 ± 0.32
e
1. " group compares with often ending
dP＜0.05,
DdP＜0.01; 2. compare with model group,
eP＜0.05,
EeP＜0.01; 3. compare with the lovastatin group,
fP＜0.05，
ffP＜0.01.
3.2. blood parameters detects
3.2.1 the variation of blood fat biochemical indicator is visible by table 2: 1. compare with normal group, model group TC significantly raises (P＜0.01), and TG, LDL-C significantly raise (P＜0.05), and HDL-C significantly reduces (P＜0.05), proves hyperlipidemia rats model modeling success; 2. compare with model group; Regulating lipid and reducing weight medicine group has significance reduction effect (P＜0.01) to TC and LDL-C; To the rising effect remarkable (P＜0.05) of HDL-C, 3. compare with the lovastatin group, regulating lipid and reducing weight medicine group has significant difference (P＜0.05) to the rising effect of HDL-C; To TC, TG influence there was no significant difference (p＞0.05), effect has significant difference (P＜0.01) to LDL-C.
Table 2 is respectively organized HDL-C in the SD rat blood serum; TC; TG, the comparison of LDL-C content
Group number of animals HDL-C (mmol/L) TC (mmol/L) TG (mmol/L) LDL-C (mmol/L)
Normal group 10 1.95 ± 0.11 2.81 ± 0.18 0.37 ± 0.07 0.83 ± 0.09
Model group 10 1.03 ± 0.40
d4.41 ± 1.11
Dd0.78 ± 0.15
d2.27 ± 0.12
Dd
Lovastatin group 10 1.09 ± 0.22 3.00 ± 0.51
Ee0.50 ± 0.04
e1.01 ± 0.11
Ee
Regulating lipid and reducing weight medicine group 10 1.83 ± 0.26
Ef3.14 ± 0.19
Ee0.59 ± 0.05 1.21 ± 0.37
Eeff
1. compare with normal group
dP＜0.05,
DdP＜0.01; 2. compare with model group,
eP＜0.05,
EeP＜0.01; 3. compare with the lovastatin group,
fP＜0.05，
ffP＜0.01.
3.2.2GLU, the variation of AST, ALT
Visible by table 3: 1. compare with normal group, hyperlipidemia model group GLU, AST, ALT all have significance rising (P＜0.05 or P＜0.01); 2. compare with model group, regulating lipid and reducing weight medicine group reduces AST, ALT effect significantly (P＜0.05), and the trend of blood sugar lowering is arranged, but not statistically significant.
Table 3 is respectively organized GLU in the SD rat blood serum; AST, the comparison of ALT content
Group number of animals GlU (mmol/L) AST (U/L) ALT (U/L)
Normal group 10 2.22 ± 0.15 104.36 ± 7.62 30.02 ± 3.52
Model group 10 3.99 ± 0.62
d197.52 ± 34.05
d57.13 ± 9.33
Dd
Lovastatin group 10 3.00 ± 0.53 110.66 ± 8.20
e30.08 ± 4.50
Ee
Regulating lipid and reducing weight medicine 10 3.73 ± 0.43 105.41 ± 10.79
e47.65 ± 7.33
e
1. compare with normal group
dP＜0.05,
DdP＜0.01; 2. compare with model group,
eP＜0.05,
EeP＜0.01; 3. compare with the lovastatin group,
fP＜0.05,
FfP＜0.01.
3.2.3 the variation of rat plasma SOD, MAD is visible by table 4: 1. compare with normal group, the big SOD activity of model group significantly reduces, MDA significantly raises (P＜0.01); 2. compare with model group, but regulating lipid and reducing weight medicine group significance rising activity of plasma SOD (P＜0.05) significantly reduces MDA content (P＜0.01, P＜0.05); 3. with the lovastatin group relatively, regulating lipid and reducing weight medicine group is active to SOD, MDA influence there was no significant difference (p＞0.05).
Table 4 is respectively organized SOD in the SD rat blood serum, the comparison of MDA content
Annotate: 1. compare with normal group
dP＜0.05,
DdP＜0.01; 2. compare with model group,
eP＜0.05,
EeP＜0.01; 3. compare with the lovastatin group,
fP＜0.05,
FfP＜0.01.
3.3. morphological observation
Table 5 aorta, cardiac muscle, liver morphological observation result
4, discuss
4.1. hyperlipemia animal replication of Model
This experiment in the animal normal feedstuff, adds 10% Adeps Sus domestica and 1% cholesterol causes artificial high fat diet, and adds 0.3% cholic acid and 0.2% propylthiouracil in the prescription.Experimental result shows: after utilizing high lipid food feed rat; The content of TC in the model group rat blood serum, TG, LDL-C all obviously raises than normal group; And HDL-C obviously descends, and proves that there is metabolism disorder of blood lipid in the model group rat, and prompting hyperlipemia experimental model duplicates successfully.
4.2. influence to body fat and body weight
Experimental result shows that model group rat body weight rate of increase, perirenal fat proportion, liver index all are significantly higher than normal group (P＜0.01 or P＜0.05).The regulating lipid and reducing weight medicine can effectively reduce the caused body weight gain of high fat diet, reduces interior fat content, liver index, can have and to a certain degree prevent the caused overweight of high fat diet, and inhibition AS is formed, reduces evidence of coronary heart diseases has good effect.
4.3. influence to blood fat
This experiment shows that the regulating lipid and reducing weight medicine can significantly reduce experimental hyperlipidemia rat blood serum LDL-C, rising HDL-C; To the latter's influence even be superior to lovastatin; So can improve the systolic and diastolic function of blood vessel, the protection blood vessel endothelium is is effectively prevented and treated the generation of atherosclerosis and coronary heart disease.Morphological observation, model group rat aorta blood vessel is rough, and vasodilation is tortuous; Became uneven, the tunica intima lipidosis, the down visible significant quantities of fat of cardiac muscular tissue's high power lens is soaked into; Regulating lipid and reducing weight medicine blood vessel is smooth; The cardiac muscle fiber even thickness does not have obvious pathological changes, and the result conforms to biochemistry detection.
4.4. influence to serum MDA, SOD
This experiment shows that model group rat blood serum MDA significantly improves, and SOD is active to be reduced, and there is the lipid peroxidation phenomenon in prompting.The regulating lipid and reducing weight medicine can improve high fat rat blood serum SOD vigor, reduces MDA, and its effect is suitable with lovastatin, shows that it has the good lipid peroxidation that alleviates, and this possibly be a key factor of its protection endotheliocyte, can delay generation and the development of AS.(height of SOD vigor can reflect antioxidant ability of organism, and the content of MDA then reflects body inner lipid peroxidating degree).
4.5. influence to liver function
Hepatocyte injury, the transaminase is overflowed in impaired hepatocyte, makes transaminase activity rising in the blood.Therefore, AST, ALT activity are the sensitive indicators of hepatocellular damage
This experiment shows, the regulating lipid and reducing weight medicine significantly reduces high fat rat blood serum AST, ALT effect, its hepatoprotective effect maybe with the anti peroxidation of lipid increased response, protect the integrity of liver plasma membrane structure relevant; The improvement of liver function and then enhancing liver reduce blood plasma LDL-C level to the adjusting of LDL-C, the protection blood vessel endothelium.Morphological observation, model group swelling of liver cell, subregion hepatic cell fattydegeneration, cell infiltration is obvious.Regulating lipid and reducing weight medicine group lobules of liver tactical rule, the hepatocyte marshalling, hepatic cell fattydegeneration and cell infiltration degree are starkly lower than model group.
4.6. influence to blood glucose
This experiment shows, feeds model group rat blood sugar significantly raise (P＜0.05) through high fat; Regulating lipid and reducing weight medicine group reduces the effect of hyperlipidemia rats blood glucose significantly.
5, conclusion
5.1. the regulating lipid and reducing weight medicine can better reduce the caused body weight gain of high fat diet, reduces body fat content, liver index;
5.2. the regulating lipid and reducing weight medicine has remarkable blood lipid regulation effect, reduces TC, TG is suitable with lovastatin, reduces the too late lovastatin of LDL-C effect, rising HDL-C effect is superior to lovastatin;
5.3. the regulating lipid and reducing weight medicine can improve high fat rat blood serum SOD vigor, reduces MDA, and good lipoid peroxidization resistant is arranged;
5.4. the regulating lipid and reducing weight medicine can be through strengthening the anti peroxidation of lipid reaction, the integrity of protection liver plasma membrane structure significantly reduces high fat rat blood serum AST, ALT;
5.5 the regulating lipid and reducing weight medicine has the effect of the high fat rat blood sugar of remarkable reduction.
(2) clinical observation on the therapeutic effect:
1. case is selected: study subject should meet following several standards:
(1) adult's empty stomach serum total cholesterol (TC) surpasses 5.72mmol/L, and triacylglycerol (TG) surpasses 1.70mmol/L, is diagnosed as hyperlipemia.
(2) affirmation was not taken fat-reducing medicament in 3 months, did not have long-term history of drinking history.
2. the mensuration result according to serum TC, TG and high density lipoprotein-cholesterol HDL-C is divided into following four types with hyperlipemia usually:
(1) hypercholesterolemia: blood TC content increases above 5.72mmol/L, and TG content is normal, i.e. TG＜1.70mmol/L.
(2) high TG mass formed by blood stasis: serum TG content increases, and surpass 1.70mmol/L, and TC content is normal, i.e. TC＜5.72mmol/L.
(3) combined hyperlipidemia familial: blood TC and TG all increase, and promptly TC surpasses 5.72mmol/L, and TG surpasses 1.70mmol/L
(4) low hdl mass formed by blood stasis: serum high-density LP-cholesterol (HDL-cholesterol) content reduction＜9.0mmol/L.
3. observational technique: the equal normal diet of all study subjects (" Chinese residents balanced diet pagoda " feed of recommending by Chinese NI), take the regulating lipid and reducing weight granule simultaneously; Be 1 course of treatment January, carries out item inspections such as TC, TG, HDL, LDL, blood glucose, liver function before and after the treatment respectively.
4. result:
5 observation case medication results that collected are following:
(1) the regulating lipid and reducing weight granule is to the influence of biochemical indicators such as blood fat
Table 6-1 regulating lipid and reducing weight granule therapy front and back are to the influence (opening * *, the woman) of blood fat, blood glucose, liver function, kidney merit
Annotate reference value TC 3.1～5.72mmol/L; TG 0.48～1.88mmol/L; LDL-C 0～3.6mmol/L; HDL-C 0.81～1.88mmol/L; GLU 3.6～6.1mmol/L; AST 0～40U/L; ALT 0～50U/L; Scr 44～97 μ mol/L; BUN 3.9～6.1mmol/L.
Table 6-2 regulating lipid and reducing weight granule therapy front and back are to the influence (Guo * *, man) of blood fat, blood glucose, liver function, kidney merit
Annotate reference value TC 3.1～5.72mmol/L; TG 0.48～1.88mmol/L; LDL-C 0～3.6mmol/L; HDL-C 0.81～1.88mmol/L; GLU 3.6～6.1mmol/L; AST 0～40U/L; ALT 0～50U/L; Scr 44～97 μ mol/L; BUN 3.9～6.1mmol/L.
Table 6-3 regulating lipid and reducing weight granule therapy front and back are to the influence (keeping * *, the man) of blood fat, blood glucose, liver function, kidney merit
Annotate reference value TC 3.1～5.72mmol/L; TG 0.48～1.88mmol/L; LDL-C 0～3.6mmol/L; HDL-C 0.81～1.88mmol/L; GLU 3.6～6.1mmol/L; AST 0～40U/L; ALT 0～50U/L; Scr 44～97 μ mol/L; BUN 3.9～6.1mmol/L.
Table 6-4 regulating lipid and reducing weight granule therapy front and back are to the influence (horse * *, woman) of blood fat, blood glucose, liver function, kidney merit
Annotate reference value TC 3.1～5.72mmol/L; TG 0.48～1.88mmol/L; LDL-C 0～3.6mmol/L; HDL-C 0.81～1.88mmol/L; GLU 3.6～6.1mmol/L; AST 0～40U/L; ALT 0～50U/L; Scr 44～97 μ mol/L; BUN 3.9～6.1mmol/L.
Table 6-5 regulating lipid and reducing weight granule therapy front and back are to the influence (Zhao * *, man) of blood fat, blood glucose, liver function, kidney merit
Annotate reference value TC 3.1～5.72mmol/L; TG 0.48～1.88mmol/L; LDL-C 0～3.6mmol/L; HDL-C 0.81～1.88mmol/L; GLU 3.6～6.1mmol/L; AST 0～40U/L; ALT 0～50U/L; Scr 44～97 μ mol/L; BUN 3.9～6.1mmol/L.
(2) the regulating lipid and reducing weight granule is to the influence of experimenter's body weight
The comparison of experimenter's body weight and Body Mass Index before and after table 7 treatment
Annotate (1) BMI=body weight (Kg)/height (rice) square.(2) obesity standard (Asia) BMI was a normal level in 18.5～22.9 o'clock, and BMI is overweight greater than 23, and BMI is fat greater than 30.
5. conclusion regulating lipid and reducing weight medicine blood lipid regulation was preferably treated after one month, and experimenter TC and TG all descend to some extent; Two to three months most of near normal, and TC, TG, LDL-C recover basically after half a year, and HDL-C has raising in various degree; Through the observation of half a year, the present invention can make experimenter's body weight that different decline is arranged in blood lipid regulation; And do not influence liver, renal function, be worth the basic place of exploitation for these article.
Most of medicine is again a food among the present invention, and determined curative effect, is suitable for prolonged application, and cheap, is easy to Application and Development.
Claims (2)
1. the Chinese medicine preparation of a regulating lipid and reducing weight, the Chinese medicine preparation that it is characterized in that this regulating lipid and reducing weight is to be processed by the former medicine of following weight portion: Herba Bidentis Bipinnatae 15-25 part, Fructus Crataegi 10-20 part, Fructus Rosae Normalis 10-20 part, Fructus Lycii 5-15 part, Radix Salviae Miltiorrhizae 10-20 part.
2. according to the Chinese medicine preparation of the said regulating lipid and reducing weight of claim 1, the Chinese medicine preparation that it is characterized in that this regulating lipid and reducing weight is to be processed by the former medicine of following weight portion: 20 parts of Herba Bidentis Bipinnatae, 15 parts of Fructus Crataegis, 15 parts of Fructus Rosae Normalis, 10 parts of Fructus Lyciis, 15 parts of Radix Salviae Miltiorrhizaes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101104160A CN101785813B (en) | 2010-02-10 | 2010-02-10 | Chinese herba preparation for regulating lipid and reducing weight |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101104160A CN101785813B (en) | 2010-02-10 | 2010-02-10 | Chinese herba preparation for regulating lipid and reducing weight |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101785813A CN101785813A (en) | 2010-07-28 |
| CN101785813B true CN101785813B (en) | 2012-06-13 |
Family
ID=42529286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101104160A Expired - Fee Related CN101785813B (en) | 2010-02-10 | 2010-02-10 | Chinese herba preparation for regulating lipid and reducing weight |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101785813B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526672B (en) * | 2012-02-03 | 2013-11-06 | 东莞广州中医药大学中医药数理工程研究院 | Traditional Chinese medicine composition, applications and preparation method |
| CN104304586A (en) * | 2014-11-03 | 2015-01-28 | 泸州岷宏科技有限公司 | Lipid-lowering tea bag and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234171A (en) * | 2008-03-06 | 2008-08-06 | 杨青华 | Health product with blood fat lowering and preventing and treating cardio-cerebralvascular disease function and preparation thereof |
-
2010
- 2010-02-10 CN CN2010101104160A patent/CN101785813B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234171A (en) * | 2008-03-06 | 2008-08-06 | 杨青华 | Health product with blood fat lowering and preventing and treating cardio-cerebralvascular disease function and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 黄川锋等.鬼针草提取物对实验性高脂血症大鼠血脂和NO及NOS的影响.《中国现代药物应用》.2009,第3卷(第17期),第14-16页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101785813A (en) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102669667B (en) | Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof | |
| CN102940733B (en) | Composition for relieving physical fatigue and preparation method and application thereof | |
| CN102846852B (en) | Composite for lowering blood fat and regulating immunity | |
| CN103083535A (en) | Dark tea composition and application in weight losing field | |
| CN101253903B (en) | Health food with fat-reducing function and its preparation | |
| CN110075216B (en) | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN103749824B (en) | A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof | |
| CN100475254C (en) | Anti-fatigue resistibility capsules for improving body immunity and method for making same | |
| KR20090021644A (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
| CN109395028A (en) | A kind of Ge Jingjia ginseng wine formula and preparation method preventing, treating three high diseases | |
| CN103520318B (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| CN101785813B (en) | Chinese herba preparation for regulating lipid and reducing weight | |
| CN102008083B (en) | Health food for alleviating physical fatigue and removing chloasma | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN106983821A (en) | A kind of pharmaceutical composition of strengthen immunity and preparation method thereof, preparation and application | |
| CN101669984A (en) | Anti-fatigue immuno-regulation Chinese medicinal product | |
| CN101317900B (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN103977390A (en) | Method for preparing ginger-onion medicinal liquor composition and application thereof | |
| CN104605051B (en) | Double numb tea containing leaves of Eucommia ulmoides and preparation method | |
| CN107441332A (en) | The ginseng composition and preparation method of auxiliary adjustment endocrine metabolism and anti-cancer and cancer-preventing | |
| CN105998196A (en) | Blood sugar decreasing healthcare pharmaceutical composition prepared from fiveleaf gynostemma herb | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN102526672A (en) | Traditional Chinese medicine composition, applications and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120613 Termination date: 20130210 |